12/11/2024

Aachen, Germany, 11 December 2024 – Grünenthal GmbH (“Grünenthal”), a pharmaceutical company specialized in treatment of pain, today announced that Grünenthal has entered into a settlement agreement with Teva Pharmaceuticals, Inc. (“Teva”) resolving their patent litigation in the U.S. in response to Teva’s Abbreviated New Drug Application (“ANDA”) seeking approval by the US. Food and Drug Administration (“FDA”) to market a generic version of Nucynta^® ER (tapentadol).

12/6/2024

Aachen, Germany, 6 December 2024 – Grünenthal GmbH (the “Company”) today announced that it has successfully placed its €500 million aggregate principal amount of 4.625% senior secured notes due 2031 (the “Notes”).

11/27/2024

Aachen, Germany, 27 November 2024 – Grünenthal GmbH (the “Company”) announces the pricing of €500 million aggregate principal amount of 4.625% senior secured notes due 2031 (the “Notes”). The Notes will be issued at 100.0%. The Notes were offered outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). In the United States, the Notes were offered only to qualified institutional buyers pursuant to Rule 144A under the Securities Act.

11/7/2024

Aachen, Germany, & Morristown, N.J., 07 November 2024 – Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001.

10/22/2024

Aachen, Germany, 22 October 2024 – Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist.

9/27/2024

Aachen, Germany, 27 September 2024 – Grünenthal announced today that Jan Adams, M.D., currently Chief Scientific Officer (CSO) and member of the Corporate Executive Board, will assume the role of Chief Commercial Officer (CCO) effective 1 October 2024. Prior to his role as CSO he was Head of Strategy and Portfolio at Grünenthal.

7/22/2024

Aachen, Germany, 22 July 2024 – Grünenthal today announced the acquisition of US-based Valinor Pharma, LLC (“Valinor”) and its product Movantik^® (naloxegol), with a total deal value of approx. $250 million inclusive of all royalty obligations. Grünenthal will finance the transaction using available liquidity.

7/17/2024

Aachen, Germany, 17 July 2024 – Grünenthal, a leading pharmaceutical company specializing in pain research and management, has announced significant investments in its Latin American production sites. These investments will enhance Grünenthal's production network, ensuring a reliable supply of medicines for patients across Latin America, Europe, and beyond.

3/25/2024

Aachen, Germany, 25 March 2024 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2023 full-year results, announcing a double-digit revenue growth.